Skip to main content
Netramark Holdings Inc. logo

Netramark Holdings Inc. — Investor Relations & Filings

Ticker · AIAI ISIN · CA64119M1059 LEI · 391200VOK8WHERIX0Q06 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 336 across all filing types
Latest filing 2021-06-08 Capital/Financing Update
Country CA Canada
Listing CSE AIAI

About Netramark Holdings Inc.

https://www.netramark.com/

Netramark Holdings Inc. develops and deploys advanced Artificial Intelligence (AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, focusing on optimizing clinical trial design and outcomes. Its core product, NetraAI, is an AI platform powered by the proprietary Attractor AI algorithm. NetraAI analyzes complex, multimodal clinical trial datasets to uncover hidden patient correlations and causal factors, providing high clarity and explainability. The platform delivers AI-powered insights to trial sponsors, clinical research organizations, and biotechnology companies. These insights are used to inform protocol design, identify optimal patient subpopulations, determine effective dosage, enhance enrichment strategies, and improve inclusion/exclusion criteria, thereby increasing effect sizes and minimizing clinical trial risks.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the closing of an oversubscribed initial public offering (IPO) of common shares by Nurosene Health Inc. It details the offering price, number of shares sold, agents involved, commissions paid, and the expected trading commencement date on the Canadian Securities Exchange. There is no financial statement or detailed financial report included, only a description of the financing event. This fits the category of a Capital/Financing Update, as it provides information on the company's fundraising activity and capital structure changes. The document length is sufficient and contains substantive details about the financing, not just a brief notice or a report publication announcement.
2021-06-08 English
Filing statement - English.PDF
Regulatory Filings Classification · 95% confidence The document is a notice to Canadian Securities Regulatory Authorities about an upcoming Special Meeting of securityholders for Starlight Hybrid Global Real Assets Trust. It provides details such as meeting type, record dates, meeting date, and location. The document is short (1077 characters) and serves as an announcement regarding the meeting and record dates, not the meeting materials or results themselves. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like AGM Information or Declaration of Voting Results.
2021-06-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Nurosene Health Inc. has filed its final long form prospectus and received conditional approval for listing on the Canadian Securities Exchange (CSE). It discusses the initial public offering (IPO) details, including share price, number of shares, and gross proceeds. The document does not contain financial statements or detailed financial analysis but rather announces the filing of a prospectus and the conditional approval for listing. It also provides a link to the prospectus on SEDAR. This fits the category of a Capital/Financing Update (CAP) because it relates to fundraising activities and capital structure changes through an IPO. The document length is over 5,000 characters and contains substantive information about the offering, not just a brief announcement of a report publication, so it is not an RPA. Therefore, the best classification is CAP with high confidence.
2021-05-25 English
Decision Document (Final).PDF
Regulatory Filings Classification · 100% confidence The document is a receipt from the Ontario Securities Commission for the filing of a Long Form Prospectus dated May 20, 2021. It is a regulatory acknowledgment of a filing rather than the prospectus itself or a detailed financial report. The document is short (888 characters) and serves as confirmation of receipt, not a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2021-05-21 English
Consent letter of underwriters' legal counsel.pdf
Capital/Financing Update Classification · 95% confidence The document is a letter from an auditing firm (Burstall LLP) addressed to various Canadian securities commissions regarding a final prospectus dated May 20, 2021. The letter consents to the use of the auditor's name in the prospectus and confirms no misrepresentations in the information they reviewed. The document is short (1198 characters) and serves as a consent letter related to a financing prospectus, not the prospectus itself or a financial report. This type of document is typically part of capital raising activities and relates to financing disclosures. Given the context and content, the document fits best under Capital/Financing Update (CAP) as it pertains to a financing prospectus and auditor consent for the offering.
2021-05-21 English
Final long form prospectus - English.PDF
Regulatory Filings
2021-05-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.